Fig. 7: SNHG12 knockdown repressed tumour progression and reversed sunitinib resistance in vivo.

a ACHN-R cells stably knockdown of SNHG12 were subcutaneously injected into nude mice. b, c The volume and weight of xenograft tumours in four groups with different treatment (n = 5). d, e Immunohistochemistry (IHC) and western blot assays were performed to measure CDCA3 expression levels in four groups with different treatment. f Schematic diagram illustrated lncRNA SNHG12 regulated SNHG12/SP1/CDCA3 axis promoting tumour progression and sunitinib resistance in RCC. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Error bars indicate mean ± SD.